Megan Sanders, Chief Executive Officer at Thoracic Oncology Group of Australasia, shared a post on LinkedIn:
“Tonight’s Federal Budget includes a significant shift for Australia’s medical research sector, with the Government committing to progressively release the full annual distribution from the Medical Research Future Fund (MRFF), increasing to $1 billion per year by 2030-31.
For the research community, this is an important outcome.
The MRFF was established to support the future of Australian medical research and innovation. Ensuring that the full authorised distribution reaches the sector matters for researchers, clinicians, consumers, and ultimately patients.
The Budget also included targeted investments in precision oncology and clinical trial access, including support for Omico and a national clinical trials navigation platform, known as the National One Stop Shop (NOSS). These investments reflect the growing importance of genomics, equitable trial access, and implementation-focused research infrastructure within Australia’s healthcare system.
At the same time, there remains a strong need to ensure that high mortality and historically underfunded disease areas continue to receive attention within future funding priorities.
Lung cancer remains Australia’s leading cause of cancer death, and improving outcomes will require continued investment across the full pipeline:
- early detection and screening,
- biomarker testing and precision medicine,
- clinical trials and translational research,
- supportive care and survivorship,
- implementation of evidence into practice.
Thoracic Oncology Group of Australasia welcomes continued investment in Australian medical research and the clinicians, researchers and consumers working to improve outcomes for people affected by thoracic cancers.”
Other articles featuring Megan Sanders on OncoDaily.